 | • レポートコード：MRC2012A9664 • 出版社/出版日：GlobalInfoResearch / 2020年12月28日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、ゼルヤンツ（トファシチニブ）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。ゼルヤンツ（トファシチニブ）薬の種類別市場規模（錠剤、徐放錠）、用途別市場規模（関節リウマチ、乾癬性関節炎、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、 ・地域別グローバル市場分析 2015年-2020年 ・ゼルヤンツ（トファシチニブ）薬の北米市場（アメリカ、カナダ、メキシコ） ・ゼルヤンツ（トファシチニブ）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・ゼルヤンツ（トファシチニブ）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・ゼルヤンツ（トファシチニブ）薬の南米市場（ブラジル、アルゼンチン） ・ゼルヤンツ（トファシチニブ）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：錠剤、徐放錠 ・用途別分析：関節リウマチ、乾癬性関節炎、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Xeljanz (tofacitnib) Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Xeljanz (tofacitnib) Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Xeljanz (tofacitnib) Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Xeljanz (tofacitnib) Drug market has been segmented into
Tablets
Extended-release Tablets
By Application, Xeljanz (tofacitnib) Drug has been segmented into:
Rheumatoid Arthritis
Psoriatic Arthritis
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Xeljanz (tofacitnib) Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Xeljanz (tofacitnib) Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Xeljanz (tofacitnib) Drug market.
The report offers in-depth assessment of the growth and other aspects of the Xeljanz (tofacitnib) Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Xeljanz (tofacitnib) Drug Market Share Analysis
Xeljanz (tofacitnib) Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Xeljanz (tofacitnib) Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Xeljanz (tofacitnib) Drug sales, revenue and market share for each player covered in this report.
The major players covered in Xeljanz (tofacitnib) Drug are:
Pfizer
Among other players domestic and global, Xeljanz (tofacitnib) Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Xeljanz (tofacitnib) Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Xeljanz (tofacitnib) Drug, with price, sales, revenue and global market share of Xeljanz (tofacitnib) Drug in 2018 and 2019.
Chapter 3, the Xeljanz (tofacitnib) Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Xeljanz (tofacitnib) Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Xeljanz (tofacitnib) Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Xeljanz (tofacitnib) Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Xeljanz (tofacitnib) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Xeljanz (tofacitnib) Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Tablets
1.2.3 Extended-release Tablets
1.3 Market Analysis by Application
1.3.1 Overview: Global Xeljanz (tofacitnib) Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriatic Arthritis
1.3.4 Other
1.4 Overview of Global Xeljanz (tofacitnib) Drug Market
1.4.1 Global Xeljanz (tofacitnib) Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Xeljanz (tofacitnib) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Xeljanz (tofacitnib) Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Xeljanz (tofacitnib) Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Xeljanz (tofacitnib) Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Xeljanz (tofacitnib) Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Xeljanz (tofacitnib) Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Xeljanz (tofacitnib) Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Xeljanz (tofacitnib) Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
4.3 Europe Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
4.5 South America Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Xeljanz (tofacitnib) Drug Sales, Revenue and Market Share by Country
5.1.1 North America Xeljanz (tofacitnib) Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Xeljanz (tofacitnib) Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
5.3 Canada Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Xeljanz (tofacitnib) Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Xeljanz (tofacitnib) Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Xeljanz (tofacitnib) Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
6.3 UK Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
6.4 France Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
6.5 Russia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
6.6 Italy Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Xeljanz (tofacitnib) Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
7.3 Japan Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
7.4 Korea Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
7.5 India Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
7.7 Australia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Xeljanz (tofacitnib) Drug Sales, Revenue and Market Share by Country
8.1.1 South America Xeljanz (tofacitnib) Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Xeljanz (tofacitnib) Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Xeljanz (tofacitnib) Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Xeljanz (tofacitnib) Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Xeljanz (tofacitnib) Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Xeljanz (tofacitnib) Drug Sales and Market Share by Type (2015-2020)
10.2 Global Xeljanz (tofacitnib) Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Xeljanz (tofacitnib) Drug Price by Type (2015-2020)
11 Global Xeljanz (tofacitnib) Drug Market Segment by Application
11.1 Global Xeljanz (tofacitnib) Drug Sales Market Share by Application (2015-2020)
11.2 Global Xeljanz (tofacitnib) Drug Revenue Market Share by Application (2015-2020)
11.3 Global Xeljanz (tofacitnib) Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Xeljanz (tofacitnib) Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Xeljanz (tofacitnib) Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Xeljanz (tofacitnib) Drug Market Forecast (2021-2025)
12.2.2 Europe Xeljanz (tofacitnib) Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Xeljanz (tofacitnib) Drug Market Forecast (2021-2025)
12.2.4 South America Xeljanz (tofacitnib) Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Xeljanz (tofacitnib) Drug Market Forecast (2021-2025)
12.3 Xeljanz (tofacitnib) Drug Market Forecast by Type (2021-2025)
12.3.1 Global Xeljanz (tofacitnib) Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Xeljanz (tofacitnib) Drug Market Share Forecast by Type (2021-2025)
12.4 Xeljanz (tofacitnib) Drug Market Forecast by Application (2021-2025)
12.4.1 Global Xeljanz (tofacitnib) Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Xeljanz (tofacitnib) Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Xeljanz (tofacitnib) Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Xeljanz (tofacitnib) Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Xeljanz (tofacitnib) Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Xeljanz (tofacitnib) Drug Major Business
Table 9. Pfizer Xeljanz (tofacitnib) Drug Total Revenue (USD Million) (2017-2018)
Table 10. Pfizer SWOT Analysis
Table 11. Pfizer Xeljanz (tofacitnib) Drug Product and Services
Table 12. Pfizer Xeljanz (tofacitnib) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Global Xeljanz (tofacitnib) Drug Sales by Manufacturer (2018-2019) (K Units)
Table 14. Global Xeljanz (tofacitnib) Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 15. Global Xeljanz (tofacitnib) Drug Sales by Regions (2015-2020) (K Units)
Table 16. Global Xeljanz (tofacitnib) Drug Sales Market Share by Regions (2015-2020)
Table 17. Global Xeljanz (tofacitnib) Drug Revenue by Regions (2015-2020) (USD Million)
Table 18. North America Xeljanz (tofacitnib) Drug Sales by Countries (2015-2020) (K Units)
Table 19. North America Xeljanz (tofacitnib) Drug Sales Market Share by Countries (2015-2020)
Table 20. North America Xeljanz (tofacitnib) Drug Revenue by Countries (2015-2020) (USD Million)
Table 21. North America Xeljanz (tofacitnib) Drug Revenue Market Share by Countries (2015-2020)
Table 22. Europe Xeljanz (tofacitnib) Drug Sales by Countries (2015-2020) (K Units)
Table 23. Europe Xeljanz (tofacitnib) Drug Sales Market Share by Countries (2015-2020)
Table 24. Europe Xeljanz (tofacitnib) Drug Revenue by Countries (2015-2020) (USD Million)
Table 25. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Regions (2015-2020) (K Units)
Table 26. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share by Regions (2015-2020)
Table 27. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue by Regions (2015-2020) (USD Million)
Table 28. South America Xeljanz (tofacitnib) Drug Sales by Countries (2015-2020) (K Units)
Table 29. South America Xeljanz (tofacitnib) Drug Sales Market Share by Countries (2015-2020)
Table 30. South America Xeljanz (tofacitnib) Drug Revenue by Countries (2015-2020) (USD Million)
Table 31. South America Xeljanz (tofacitnib) Drug Revenue Market Share by Countries (2015-2020)
Table 32. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Countries (2015-2020) (K Units)
Table 33. Middle East & Africa Xeljanz (tofacitnib) Drug Sales Market Share by Countries (2015-2020)
Table 34. Middle East & Africa Xeljanz (tofacitnib) Drug Revenue by Countries (2015-2020) (USD Million)
Table 35. Middle East & Africa Xeljanz (tofacitnib) Drug Revenue Market Share by Countries (2015-2020)
Table 36. Global Xeljanz (tofacitnib) Drug Sales by Type (2015-2020) (K Units)
Table 37. Global Xeljanz (tofacitnib) Drug Sales Share by Type (2015-2020)
Table 38. Global Xeljanz (tofacitnib) Drug Revenue by Type (2015-2020) (USD Million)
Table 39. Global Xeljanz (tofacitnib) Drug Revenue Share by Type (2015-2020)
Table 40. Global Xeljanz (tofacitnib) Drug Sales by Application (2015-2020) (K Units)
Table 41. Global Xeljanz (tofacitnib) Drug Sales Share by Application (2015-2020)
Table 42. Global Xeljanz (tofacitnib) Drug Sales Forecast by Regions (2021-2025) (K Units)
Table 43. Global Xeljanz (tofacitnib) Drug Market Share Forecast by Regions (2021-2025)
Table 44. Global Xeljanz (tofacitnib) Drug Sales Forecast by Type (2021-2025) (K Units)
Table 45. Global Xeljanz (tofacitnib) Drug Market Share Forecast by Type (2021-2025)
Table 46. Global Xeljanz (tofacitnib) Drug Sales Forecast by Application (2021-2025)
Table 47. Global Xeljanz (tofacitnib) Drug Market Share Forecast by Application (2021-2025)
Table 48. Direct Channel Pros & Cons
Table 49. Indirect Channel Pros & Cons
Table 50. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Xeljanz (tofacitnib) Drug Picture
Figure 2. Global Sales Market Share of Xeljanz (tofacitnib) Drug by Type in 2019
Figure 3. Tablets Picture
Figure 4. Extended-release Tablets Picture
Figure 5. Xeljanz (tofacitnib) Drug Sales Market Share by Application in 2018
Figure 6. Rheumatoid Arthritis Picture
Figure 7. Psoriatic Arthritis Picture
Figure 8. Other Picture
Figure 9. Global Xeljanz (tofacitnib) Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Xeljanz (tofacitnib) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Xeljanz (tofacitnib) Drug Sales Market Share by Manufacturer in 2019
Figure 30. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Xeljanz (tofacitnib) Drug Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Xeljanz (tofacitnib) Drug Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 35. Global Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Regions (2015-2020)
Figure 37. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Regions in 2018
Figure 38. North America Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
Figure 39. Europe Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
Figure 41. South America Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020)
Figure 43. North America Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Xeljanz (tofacitnib) Drug Sales Market Share by Countries (2015-2020)
Figure 45. North America Xeljanz (tofacitnib) Drug Sales Market Share by Countries in 2018
Figure 46. North America Xeljanz (tofacitnib) Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Xeljanz (tofacitnib) Drug Revenue Market Share by Countries in 2018
Figure 48. United States Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 49. Canada Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Mexico Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Europe Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Xeljanz (tofacitnib) Drug Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Xeljanz (tofacitnib) Drug Revenue Market Share by Countries in 2019
Figure 54. Germany Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 55. UK Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 56. France Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 57. Russia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Italy Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue Market Share by Regions 2019
Figure 62. China Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Japan Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Korea Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 65. India Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Southeast Asia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 67. South America Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Xeljanz (tofacitnib) Drug Sales Market Share by Countries in 2019
Figure 69. South America Xeljanz (tofacitnib) Drug Revenue Market Share by Countries in 2019
Figure 70. Brazil Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Argentina Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Middle East and Africa Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Xeljanz (tofacitnib) Drug Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Xeljanz (tofacitnib) Drug Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Egypt Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Turkey Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 79. South Africa Xeljanz (tofacitnib) Drug Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Global Xeljanz (tofacitnib) Drug Sales and Growth Rate (2021-2025) (K Units)
Figure 81. Global Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Xeljanz (tofacitnib) Drug Market Forecast (2021-2025) (K Units)
Figure 83. Europe Sales Xeljanz (tofacitnib) Drug Market Forecast (2021-2025) (K Units)
Figure 84. Asia-Pacific Sales Xeljanz (tofacitnib) Drug Market Forecast (2021-2025) (K Units)
Figure 85. South America Sales Xeljanz (tofacitnib) Drug Market Forecast (2021-2025) (K Units)
Figure 86. Middle East & Africa Sales Xeljanz (tofacitnib) Drug Market Forecast (2021-2025) (K Units)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel
関節リウマチ治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Rheumatoid Arthritis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Rheumatoid Arthriti…- 乾癬性関節炎治療薬の世界市場（～2026年） Psoriatic arthritis is a long-term inflammatory arthritis that occurs in people affected by the autoimmune disease psoriasis. The global psoriatic arthritis therapeutics market is expected to grow rapidly over the forecast period owing to the increasing prevalence rate of psoriatic arthritis. Market…
- 血清反応陽性用関節リウマチ治療薬の世界市場（～2026年） Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet. The Americas dominated the overall market in terms of revenue in 2016 owing to the…
- 関節炎薬の世界市場（～2026年） Arthritis is condition that causes pain and inflammation in joints. Around 100 different types of arthritis related conditions present globally and it is one of the leading cause of disability worldwide. The most common types of arthritis includes: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoart…
- 関節リウマチ治療の世界市場（～2026年） Rheumatoid arthritis is a long-term autoimmune disorder that primarily affects joints. The rheumatoid arthritis treatment market is expected to grow over the forecast period owing to the high incidence rate of rheumatoid arthritis among people. Market Analysis and Insights: Global Rheumatoid Arthrit…